RESEARCH PROFILE
GLUTATHIONE
Endogenous Tripeptide • Antioxidant & Cellular Redox Research
Glutathione is a naturally occurring tripeptide composed of glutamate, cysteine, and glycine. It is one of the body's principal intracellular antioxidants and plays important roles in cellular redox balance, detoxification pathways, and protection against oxidative stress.
Research has investigated glutathione supplementation through oral, liposomal, sublingual, intranasal, and intravenous routes. Injectable intramuscular and subcutaneous administration is also described in clinical-practice and community literature, although direct controlled human evidence supporting these routes remains limited.
ENDOGENOUS COMPOUND • ORAL SUPPLEMENT AVAILABLE • INJECTABLE USES NOT FDA APPROVED FOR GENERAL WELLNESS
← CELLULAR & LONGEVITY RESEARCH
GLUTATHIONE AT A GLANCE
Category
Antioxidant and cellular redox research compound
Also Known As
GSH • Reduced Glutathione • γ-Glutamyl-Cysteinyl-Glycine
Structure
Three amino acid tripeptide composed of glutamate, cysteine, and glycine
Primary Research Focus
Oxidative stress • Cellular antioxidant defense • Redox balance • Skin pigmentation • Liver metabolism
Regulatory Status
Oral dietary supplement ingredient; injectable glutathione is not FDA approved for general wellness, skin lightening, or cosmetic use
Human Evidence
Human studies involving oral, intranasal, and intravenous administration; limited direct controlled evidence for intramuscular and subcutaneous administration
Glutathione is synthesized naturally within cells and participates in antioxidant defense by donating electrons to neutralize reactive oxygen species.
Its reduced form, GSH, can be converted into oxidized glutathione, GSSG, during antioxidant reactions. Cellular systems subsequently regenerate GSH using reducing equivalents, including NADPH.
Human studies have investigated glutathione supplementation for oxidative stress, skin pigmentation, liver-related outcomes, and neurological conditions.
However, findings differ substantially by route, formulation, dose, and study population. Evidence supporting a particular route should not automatically be transferred to another.
WHAT IS GLUTATHIONE?
Glutathione is a naturally occurring antioxidant tripeptide found throughout the human body.
It consists of three amino acids:
Glutamate
Cysteine
Glycine
Unlike many experimental peptides, glutathione is not a newly designed synthetic signaling molecule. It is an essential component of normal cellular physiology.
Glutathione is especially important in tissues exposed to oxidative stress and metabolic activity, including the liver, kidneys, lungs, and immune system.
Its primary functions include:
Maintaining intracellular antioxidant defenses
Participating in cellular redox reactions
Supporting glutathione-dependent detoxification pathways
Helping maintain protein thiol balance
Participating in cellular responses to oxidative and inflammatory stress
The liver is a major site of glutathione synthesis and metabolism, although glutathione is produced in many tissues.
Glutathione levels can be influenced by nutritional status, precursor availability, oxidative stress, aging, disease, and cellular metabolic activity.
Supplementation research has therefore explored whether increasing glutathione availability can influence biological markers or clinical outcomes.
An important distinction is that glutathione is essential to normal health, but this does not establish that supplemental or injectable glutathione improves health outcomes in otherwise healthy individuals.
MECHANISM OF ACTION
Glutathione participates in several interconnected biochemical systems involved in cellular protection, antioxidant recycling, and metabolism.
ANTIOXIDANT DEFENSE
Reduced glutathione acts as an electron donor in reactions that neutralize reactive oxygen species and organic peroxides.
Glutathione peroxidase enzymes use GSH to help reduce hydrogen peroxide and lipid hydroperoxides.
During these reactions, reduced glutathione is converted into oxidized glutathione.
This process helps limit oxidative damage to cellular membranes, proteins, and other structures.
GSH AND GSSG REDOX BALANCE
Glutathione exists primarily in two interconnected forms:
GSH: Reduced glutathione
GSSG: Oxidized glutathione
The relationship between these forms is an important indicator of cellular redox status.
Glutathione reductase uses NADPH to convert GSSG back into GSH.
This recycling process allows glutathione to participate repeatedly in antioxidant reactions.
GLUTATHIONE SYNTHESIS
Glutathione synthesis occurs through a two-step enzymatic process.
The first step combines glutamate and cysteine through glutamate-cysteine ligase.
The second step adds glycine through glutathione synthetase.
Cysteine availability is frequently an important limiting factor.
This is one reason N-acetylcysteine, or NAC, is studied as a precursor that may support endogenous glutathione production.
NAC is not glutathione itself.
DETOXIFICATION PATHWAYS
Glutathione participates in Phase II metabolism through glutathione S-transferase enzymes.
These enzymes facilitate the conjugation of glutathione with certain electrophilic compounds, including some reactive metabolic intermediates.
This can support subsequent processing and elimination.
However, describing glutathione as a universal substance that removes toxins from the body oversimplifies its biological role.
SKIN PIGMENTATION
Glutathione has also been investigated for effects on melanin production.
Proposed mechanisms include interference with tyrosinase-related pathways and changes in the relative production of eumelanin and pheomelanin.
Human studies have reported modest changes in pigmentation measurements in some settings.
These effects have generally been small, and the available evidence does not establish permanent skin-lightening benefits.
IMPORTANT MECHANISM LIMITATION
Glutathione's biochemical functions are well established.
What remains less certain is whether administering additional glutathione through a particular formulation or route consistently produces meaningful clinical benefits.
Mechanistic plausibility should not be treated as proof of therapeutic effectiveness.
WHAT THE RESEARCH SHOWS
HUMAN CLINICAL RESEARCH
Glutathione has been investigated in human studies involving several administration routes.
The evidence is not uniform.
Oral, liposomal, intranasal, intravenous, intramuscular, and subcutaneous delivery differ in absorption, systemic exposure, safety considerations, and available clinical research.
ORAL GLUTATHIONE RESEARCH
Oral glutathione has been studied for its potential effects on glutathione stores and oxidative stress markers.
One randomized controlled trial evaluated oral supplementation over approximately six months and reported increases in selected glutathione measurements.
Other studies have reported smaller effects or inconsistent changes.
The literature therefore does not establish that all oral glutathione products produce equivalent increases in intracellular glutathione.
Formulation, dose, treatment duration, and measurement method may influence results.
SKIN PIGMENTATION RESEARCH
Several human studies have examined oral glutathione for effects on skin pigmentation.
The Project source describes randomized trials using approximately 250–1,000 mg daily, with study durations ranging from several weeks to several months.
A systematic review summarized evidence suggesting modest reductions in melanin index in some treatment groups.
However, the reported effects were generally limited, and pigmentation changes were not consistently durable after discontinuation.
These findings do not establish glutathione as an FDA-approved skin-lightening treatment.
LIVER & METABOLIC RESEARCH
A small open-label study evaluated oral glutathione in patients with nonalcoholic fatty liver disease.
Participants received 300 mg daily for four months.
The study reported changes in selected liver-related measurements, including alanine aminotransferase.
However, the study lacked a placebo-controlled comparison group.
Therefore, these findings should be regarded as preliminary rather than proof that glutathione treats fatty liver disease.
PARKINSON'S DISEASE RESEARCH
Intranasal and intravenous glutathione have been investigated in Parkinson's disease.
The Project source describes a randomized trial of intranasal glutathione in which treatment was generally tolerated, but the primary clinical benefit was not convincingly established over placebo.
Earlier intravenous studies also produced mixed or inconclusive findings.
Glutathione is not an established treatment for Parkinson's disease.
INTRAVENOUS RESEARCH
Intravenous glutathione bypasses gastrointestinal absorption and produces a different exposure profile from oral supplementation.
Clinical studies have examined IV glutathione in neurological and other research settings.
The Project source describes research regimens involving approximately 600–1,200 mg per administration.
These amounts reflect specific study contexts and should not be interpreted as a general clinical protocol.
Intravenous administration introduces additional concerns involving infusion reactions, product quality, contamination, and sterility.
INTRAMUSCULAR & SUBCUTANEOUS RESEARCH
The Project source describes intramuscular and subcutaneous glutathione administration in functional-medicine and community settings.
It identifies commonly reported amounts in the 200–600 mg range, generally discussed several times weekly.
These are community or clinical-practice reports, not validated dosing recommendations established by controlled human efficacy trials.
The source does not establish a standardized FDA-approved intramuscular or subcutaneous regimen.
Nor does it demonstrate that these routes produce the same effects observed in oral, intranasal, or intravenous research.
LIPOSOMAL & SUBLINGUAL FORMULATIONS
Liposomal and sublingual products are intended to alter delivery or absorption compared with conventional oral formulations.
Small studies have investigated whether these approaches improve glutathione availability.
However, comparative human evidence remains limited, and results should not be generalized across products.
IMPORTANT EVIDENCE LIMITATIONS
There is currently:
No established FDA-approved injectable glutathione protocol for general wellness or cosmetic skin lightening
Limited controlled human evidence supporting intramuscular or subcutaneous glutathione administration
No established evidence that routine glutathione injections improve longevity
No convincing evidence that glutathione supplementation permanently lightens skin
Insufficient evidence to establish glutathione as a treatment for Parkinson's disease
Insufficient controlled evidence establishing glutathione as an effective treatment for fatty liver disease
Glutathione is biologically important, but its established cellular functions should not be confused with proven benefits from supplemental administration.
SAFETY & RESEARCH CONSIDERATIONS
Glutathione is naturally produced by the body, but that does not mean all supplemental formulations or administration routes are equally safe.
Safety depends on the formulation, dose, route, product quality, individual health conditions, and other medications.
ORAL GLUTATHIONE
Reported adverse effects in oral studies have generally been mild.
These may include:
Abdominal discomfort
Bloating
Loose stools
Nausea
Mild gastrointestinal irritation
Long-term safety information varies by formulation and study population.
INTRAVENOUS GLUTATHIONE
Intravenous administration introduces additional risks beyond those associated with oral supplementation.
Potential concerns include:
Nausea
Flushing
Headache
Infusion-related reactions
Allergic or hypersensitivity reactions
Contamination or sterility failures
Errors in preparation or administration
The Project source also discusses reports of serious adverse events associated with improperly prepared injectable glutathione products.
INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION
Potential injection-related adverse effects include:
Injection-site discomfort
Redness
Swelling
Local irritation
Infection
Hypersensitivity reactions
The absence of extensive published adverse-event data does not establish that these routes are safe.
PRODUCT QUALITY & STERILITY
Injectable glutathione requires particular attention to pharmaceutical quality.
Potential concerns include:
Incorrect concentration
Contamination
Endotoxin exposure
Degradation
Incorrect product identity
Sterility failure
Improper preparation or storage
A laboratory report confirming chemical purity does not necessarily establish that a product is sterile, suitable for injection, or safe for human administration.
SKIN PIGMENTATION EFFECTS
Glutathione has been associated with changes in skin pigmentation in some clinical studies.
For some individuals, these changes may be an intended cosmetic outcome.
For others, they may be unwanted.
The long-term safety of repeated glutathione administration specifically for cosmetic skin lightening has not been established.
DRUG INTERACTIONS
The Project source identifies potential concerns involving medications metabolized through hepatic pathways, including certain chemotherapy agents.
Glutathione participates in cellular responses to oxidative stress and drug metabolism.
However, the clinical significance of interactions with individual medications is not fully established.
Individuals receiving cancer treatment or taking prescription medications should discuss glutathione supplementation with their treating clinician.
PREGNANCY & BREASTFEEDING
Adequate clinical evidence establishing the safety of supplemental or injectable glutathione during pregnancy or breastfeeding is lacking.
ASTHMA & HYPERSENSITIVITY
The Project source identifies reports of bronchospasm associated with inhaled or nebulized glutathione.
Individuals with asthma or a history of hypersensitivity reactions require particular caution.
ZINC DEPLETION
The Project source mentions theoretical concerns about zinc depletion with prolonged high-dose glutathione use.
However, clinically meaningful zinc depletion from glutathione supplementation has not been established as a consistent human adverse effect.
Routine mineral testing should not be presented as universally necessary solely because someone uses glutathione.
MONITORING CONSIDERATIONS
Depending on the clinical context, a qualified healthcare professional may consider:
Liver function tests
Kidney function
Medication review
Symptoms of hypersensitivity
Injection-site complications
Relevant oxidative stress or glutathione biomarkers in research settings
Monitoring should be individualized rather than based on an unvalidated universal protocol.
REGULATORY CONTEXT
GLUTATHIONE IS NOT FDA APPROVED FOR GENERAL WELLNESS INJECTION
Glutathione is naturally produced by the human body and is available as an ingredient in dietary supplements.
However, its presence in the body does not establish regulatory approval for injectable use.
ORAL DIETARY SUPPLEMENTS
Oral glutathione products are marketed as dietary supplements in the United States.
Dietary supplements are not approved by the FDA before marketing in the same manner as prescription drugs.
Their availability does not establish that they are effective for treating or preventing disease.
INJECTABLE GLUTATHIONE
Injectable glutathione is not FDA approved for general wellness, anti-aging, detoxification, or cosmetic skin lightening.
Compounded preparations may be subject to different regulatory requirements, but compounding does not establish FDA approval or clinical effectiveness.
FDA SAFETY CONCERNS
The FDA has documented safety concerns involving injectable glutathione preparations, including reports associated with endotoxin contamination.
In 2019, FDA described adverse reactions in patients who received intravenous glutathione prepared from ingredients with unsuitable endotoxin specifications.
This illustrates why injectable product quality, pharmaceutical sourcing, and sterility are independent safety concerns.
SKIN LIGHTENING
The FDA has not approved injectable glutathione for cosmetic skin lightening.
The Project source also references regulatory warnings from the Philippines concerning injectable glutathione marketed for this purpose.
IMPORTANT REGULATORY DISTINCTION
The most accurate website language is:
Glutathione is an endogenous antioxidant and an ingredient in oral dietary supplements. Injectable glutathione is not FDA approved for general wellness, cosmetic skin lightening, or anti-aging. Human research exists, but evidence and safety differ substantially by route and indication.
Natural occurrence, dietary supplement availability, and published clinical studies should not be presented as FDA approval of injectable glutathione.
ANALYTICAL DOCUMENTATION
Croix maintains available third party analytical documentation for specific samples and lots represented in its research library.
GLUTATHIONE 1500 MG
The Croix Project catalog identifies:
Glutathione — 1500 mg
LOT SPECIFIC ANALYTICAL DOCUMENTATION
Analytical documentation is displayed only when Croix has a corresponding laboratory report that can be matched to the specific product and lot.
No matching Glutathione COA is currently displayed.
IMPORTANT COA LIMITATION
When analytical documentation becomes available, results should be presented only for the specific sample and lot identified in the laboratory report.
A Certificate of Analysis for one sample does not establish the composition, purity, sterility, safety, efficacy, or characteristics of another sample, lot, batch, or product.
Croix's Project standard specifically requires matching the product, strength, lot or batch, sample ID, laboratory, and report date before analytical documentation is presented.
A COA for another glutathione product, vial strength, sample, or batch should not be represented as verification of the Croix Glutathione 1500 mg product.
SELECTED RESEARCH & REFERENCES
Richie JP Jr, et al.
Randomized controlled trial of oral glutathione supplementation on body stores of glutathione.
European Journal of Nutrition. 2015.
Human randomized trial examining glutathione stores during oral supplementation.
Allen J, Bradley RD.
Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers.
Journal of Alternative and Complementary Medicine. 2011.
Human research examining oxidative stress biomarkers and oral glutathione supplementation.
Arjinpathana N, Asawanonda P.
Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study.
Journal of Dermatological Treatment. 2012.
Randomized human study investigating oral glutathione and skin pigmentation.
Handog EB, Datuin MS, Singzon IA.
An open-label, single-arm trial of a glutathione lozenge as a skin-lightening agent in Filipino women.
International Journal of Dermatology. 2016.
Human research involving a buccal glutathione formulation.
Sarkar R, et al.
Glutathione as a skin-lightening agent and in melasma: a systematic review.
International Journal of Dermatology. 2025.
Review examining human evidence for glutathione and pigmentation outcomes.
Weschawalit S, Thongthip S, Phutrakool P, Asawanonda P.
Glutathione and its antiaging and antimelanogenic effects.
Clinical, Cosmetic and Investigational Dermatology. 2017.
Clinical research examining glutathione and skin-related outcomes.
Honda Y, et al.
Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study.
BMC Gastroenterology. 2017.
Preliminary human research examining oral glutathione in fatty liver disease.
Mischley LK, Lau RC, Shankland EG, Wilbur TK, Padowski JM.
Phase IIb study of intranasal glutathione in Parkinson's disease.
Journal of Parkinson's Disease. 2017.
Clinical research examining intranasal glutathione in Parkinson's disease.
Mischley LK, Leverenz JB, Lau RC, et al.
A randomized, double-blind phase IIb study of intranasal glutathione in Parkinson's disease.
Movement Disorders. 2016.
Randomized human research involving intranasal glutathione.
Schmitt B, et al.
A targeted metabolomics assessment of oral glutathione bioavailability and safety in humans: a randomized crossover clinical trial.
Antioxidants. 2025.
Human research examining oral glutathione bioavailability.
U.S. Food & Drug Administration
FDA Highlights Concerns with Using Dietary Ingredient Glutathione to Compound Sterile Injectables.
FDA safety communication. 2019.
Regulatory safety information concerning injectable glutathione preparation and endotoxin-related adverse reactions.
U.S. Food & Drug Administration, Philippines
FDA Advisory No. 2019-182: Unsafe Use of Glutathione as Skin-Lightening Agent.
2019.
Regulatory warning regarding injectable glutathione for cosmetic skin lightening.
Pharmacological research on N-acetylcysteine
Research examining NAC as a precursor involved in intracellular glutathione synthesis.
NAC-related findings should not automatically be interpreted as clinical evidence for direct glutathione administration.
RESEARCH INTERPRETATION
The cited literature includes randomized controlled trials, open-label studies, systematic reviews, and regulatory safety communications.
These sources do not all provide the same level of evidence.
In particular, controlled human evidence involving oral glutathione should not be represented as direct validation of intramuscular or subcutaneous glutathione protocols.
RESEARCH & EDUCATIONAL INFORMATION
This profile is provided for research and educational reference. It does not constitute individualized medical advice or establish supplemental or injectable glutathione as safe or effective for personal use.
Glutathione is an essential endogenous antioxidant involved in cellular redox balance, but its physiological importance does not establish that supplementation improves longevity, detoxification, skin health, liver disease, neurological conditions, or general wellness outcomes.
Published human research has investigated several administration routes, including oral, buccal, intranasal, and intravenous glutathione.
Evidence supporting intramuscular and subcutaneous administration remains substantially more limited, and community-reported protocols should not be interpreted as validated clinical treatment schedules.
Injectable glutathione is not FDA approved for general wellness, cosmetic skin lightening, or anti-aging.
Analytical documentation presented by Croix applies only to the specific samples and lots identified in corresponding laboratory reports.
No matching Certificate of Analysis is currently displayed for Croix Glutathione 1500 mg.